Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy (EmNa)
|ClinicalTrials.gov Identifier: NCT00571168|
Recruitment Status : Unknown
Verified January 2010 by Heidelberg University.
Recruitment status was: Recruiting
First Posted : December 11, 2007
Last Update Posted : January 12, 2010
Scientific background In patients with multiple myeloma high-dose chemotherapy followed by autologous stemcell transplantation is preferred to conventional therapy, since the superiority in respect to complete remission, complete remission duration, event-free survival and overall survival has been proven within well controlled clinical trials (Fassas et al., 2002; Goldschmidt et al., 2003).
Nausea and vomiting are well known and the most distressing side-effects of a high dose chemotherapy regimen. The administration of selective 5-HT3-receptor antagonists (5-HT3 RAs) in combination with a corticosteroid (= antiemetic standard therapy) is effective for the prevention of those adverse effects in 70 to 80 % of patients. However, 25 to 40 % of the patients still suffer from vomiting and nausea in the delayed phase of the chemotherapy. Superior protection could be achieved with the addition of Aprepitant (EMEND®) to the antiemetic standard therapy in acute and delayed phases of highly emetogenic chemotherapies. The enhanced antiemetic protection can be maintained over multiple chemotherapy-cycles to an extent superior to that of standard therapy alone (de Wit et al., 2003).
Furthermore addition of Aprepitant (EMEND®) to standard therapy was generally well tolerated and the impact of chemotherapy-induced nausea and vomiting (CINV) on daily life was significantly reduced (Hesketh et al., 2003; Dando & Perry, 2004).
- Trial Rationale Aprepitant (EMEND®) is a selective high-affinity receptor antagonist of human substance P/neurokinin-1 (NK1) and has been shown to inhibit emesis induced by cytotoxic chemotherapeutic agents and augments the antiemetic activity of 5-HT3 RAs (e.g. Granisetron, Ondansetron) and corticosteroids (e.g. Dexamethasone). Thus Aprepitant (EMEND®) in addition to antiemetic standard therapy has been shown to possess powerful superior protection and has been reported in several clinical trials to significantly improve both acute and delayed CINV.
The aim of this study is to evaluate, during and up to 7 days after high-dose chemotherapy with Melphalan (moderate emetogenic drug) followed by autologous peripheral blood stemcell transplantation, an antiemetic treatment regimen in respect to efficacy and safety in patients with multiple myeloma. To the best of our knowledge effects of Aprepitant on Melphalan induced CINV have never been investigated.
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Drug: Emend Drug: Placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||362 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Randomised, Placebo Controlled, Single-center, Double-blind Clinical Trial to Investigate Efficacy and Safety of Aprepitant Combined With Kevatril and Dexamethasone Versus Placebo Combined With Kevatril and Dexamethasone in Prevention of Acute and Delayed High-dose Chemotherapy-induced Nausea and Vomiting in Subjects With Multiple Myeloma Receiving an Autologous Peripheral Blood Stemcell Transplantation.|
|Study Start Date :||July 2005|
|Estimated Primary Completion Date :||December 2010|
|Estimated Study Completion Date :||December 2010|
U.S. FDA Resources
Aprepitant plus standard therapy (Kevatril + Dexamethason) on day 1-4
125 mg/d on day 1; 80 mg/d on day 2-4
Placebo Comparator: B
Placebo plus standard therapy (Kevatril + Dexamethason) on day 1-4
Placebo capsules on day 1-4
- Overall complete response (no emesis and no rescue therapy) [ Time Frame: During and post chemotherapy (0-120 h) ]
- Complete response acute/delayed phase [ Time Frame: During and post chemotherapy (0-120h) ]
- Vomiting event rate [ Time Frame: During and post chemotherapy (0-120h) ]
- No emesis (FLIE-Score) [ Time Frame: During and post chemotherapy (0-120h) ]
- No (significant) nausea (VAS < 5 mm;(< 25 mm)) [ Time Frame: During and post chemotherapy (0-120h) ]
- No rescue therapy [ Time Frame: During and post chemotherapy (0-120h) ]
- Total control (no emesis, no nausea, no rescue therapy) [ Time Frame: During and post chemotherapy (0-120h) ]
- No impact on daily life [ Time Frame: During and post chemotherapy (0-120h) ]
- AEs [ Time Frame: During and post chemotherapy (0-120h) ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00571168
|Contact: Gerlinde Egerer, MD||++49(0)6221 56-8002||Gerlinde.Egerer@med.uni-heidelberg.de|
|University Hospital of Heidelberg, Department V||Recruiting|
|Heidelberg, Germany, 69120|
|Principal Investigator: Gerlinde Egerer, MD|
|Principal Investigator:||Gerlinde Egerer, MD||University Hospital of Heidelberg; Im Neuenheimer Feld 410; 69120 Heidelberg/ Germany|